MX2020004240A - Proceso para generar composiciones terapeuticas de celulas modificadas. - Google Patents
Proceso para generar composiciones terapeuticas de celulas modificadas.Info
- Publication number
- MX2020004240A MX2020004240A MX2020004240A MX2020004240A MX2020004240A MX 2020004240 A MX2020004240 A MX 2020004240A MX 2020004240 A MX2020004240 A MX 2020004240A MX 2020004240 A MX2020004240 A MX 2020004240A MX 2020004240 A MX2020004240 A MX 2020004240A
- Authority
- MX
- Mexico
- Prior art keywords
- cells
- therapeutic compositions
- engineered cells
- aspects
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/32—T-cell receptors [TCR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/16—Particles; Beads; Granular material; Encapsulation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762580409P | 2017-11-01 | 2017-11-01 | |
| US201762596771P | 2017-12-08 | 2017-12-08 | |
| US201862721603P | 2018-08-22 | 2018-08-22 | |
| PCT/US2018/058590 WO2019089855A1 (en) | 2017-11-01 | 2018-10-31 | Process for generating therapeutic compositions of engineered cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004240A true MX2020004240A (es) | 2020-09-25 |
Family
ID=64362686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004240A MX2020004240A (es) | 2017-11-01 | 2018-10-31 | Proceso para generar composiciones terapeuticas de celulas modificadas. |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US12258580B2 (https=) |
| EP (2) | EP3704230B1 (https=) |
| JP (2) | JP7357626B2 (https=) |
| KR (1) | KR20200099132A (https=) |
| CN (1) | CN111542596B (https=) |
| AU (2) | AU2018360599A1 (https=) |
| BR (1) | BR112020008340A2 (https=) |
| CA (1) | CA3084514A1 (https=) |
| DK (1) | DK3704230T3 (https=) |
| ES (1) | ES2999361T3 (https=) |
| FI (1) | FI3704230T3 (https=) |
| IL (1) | IL274293B2 (https=) |
| MA (1) | MA50855A (https=) |
| MX (1) | MX2020004240A (https=) |
| PL (1) | PL3704230T3 (https=) |
| PT (1) | PT3704230T (https=) |
| SG (1) | SG11202003688PA (https=) |
| WO (1) | WO2019089855A1 (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| WO2019113557A1 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| KR20210104713A (ko) | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| KR102624804B1 (ko) * | 2018-11-16 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 결합 쌍의 부재를 갖는 스트렙타비딘 코팅된 고체상 |
| PL3886894T3 (pl) | 2018-11-30 | 2024-07-01 | Juno Therapeutics, Inc. | Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej |
| PL3886875T3 (pl) | 2018-11-30 | 2024-09-09 | Juno Therapeutics, Inc. | Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej |
| KR20220004028A (ko) * | 2019-04-26 | 2022-01-11 | 알로젠 테라퓨틱스 인코포레이티드 | 동종 car t 세포를 제조하는 방법 |
| CA3142108A1 (en) * | 2019-05-28 | 2020-12-03 | Miltenyi Biotec B.V. & Co. KG | Method for generation of genetically modified t cells |
| US20220412954A1 (en) | 2019-11-05 | 2022-12-29 | Juno Therapeutics, Inc. | Methods of determining attributes of therapeutic t cell compositions |
| IL293393A (en) | 2019-12-06 | 2022-07-01 | Juno Therapeutics Inc | Cell therapy-related toxicity and response-related methods for the treatment of b-cell malignancies |
| JP2023513434A (ja) | 2020-01-24 | 2023-03-31 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法 |
| US20230201440A1 (en) * | 2020-05-08 | 2023-06-29 | Innovative Cellular Therapeutics Holdings, Ltd. | System and method for gene and/or cellular therapy |
| JP7727662B2 (ja) | 2020-05-13 | 2025-08-21 | ジュノー セラピューティクス インコーポレイテッド | 臨床応答に関連する特徴量の特定方法およびその使用 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| KR20230159851A (ko) | 2021-03-22 | 2023-11-22 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 결정하는 방법 |
| TWI828009B (zh) * | 2021-11-19 | 2024-01-01 | 財團法人工業技術研究院 | 免標記式細胞活性檢測的方法及訓練人工智慧執行免標記式細胞活性檢測的方法 |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| CN121100267A (zh) | 2022-12-09 | 2025-12-09 | 朱诺治疗学股份有限公司 | 使用全息成像预测细胞表型的机器学习方法 |
| KR20260005874A (ko) | 2023-02-28 | 2026-01-12 | 주노 쎄러퓨티크스 인코퍼레이티드 | 전신 자가면역 질환을 치료하기 위한 세포 요법 |
| KR20250169631A (ko) | 2023-04-18 | 2025-12-03 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료 세포 조성물의 효력을 평가하기 위한 세포독성 검정 |
| WO2024226858A1 (en) | 2023-04-26 | 2024-10-31 | Juno Therapeutics, Inc. | Methods for viral vector manufacturing |
| CN121464348A (zh) | 2023-05-23 | 2026-02-03 | 朱诺治疗学股份有限公司 | T细胞的激活标记物和评估t细胞激活的方法 |
| WO2025024310A2 (en) * | 2023-07-21 | 2025-01-30 | Kyverna Therapeutics, Inc. | Methods for rapid manufacture of engineered t cells expressing chimeric antigen receptors |
| KR102684935B1 (ko) * | 2024-02-22 | 2024-07-17 | 유진산업개발 주식회사 | 폴리우레아 수지 방수제 및 이를 이용한 방수 공법 |
| WO2025196582A1 (en) * | 2024-03-18 | 2025-09-25 | Immuneel Therapeutics Private Limited | A method for preparing chimeric antigen receptor (car) expressing cells |
| WO2025231444A1 (en) * | 2024-05-02 | 2025-11-06 | R.P. Scherer Technologies, Llc | Lentiviral vectors incorporating linker and tag systems for car detection |
| WO2026020055A2 (en) | 2024-07-18 | 2026-01-22 | Juno Therapeutics, Inc. | Methods for assessing exosomes in a cell composition and related uses |
| WO2026050426A2 (en) | 2024-08-28 | 2026-03-05 | Juno Therapeutics, Inc. | Cd19-directed chimeric antigen receptor cell therapy for treating autoimmune and neurological diseases |
| CN119424317A (zh) * | 2024-11-14 | 2025-02-14 | 山东大学 | 一种小鼠干性car-t细胞及其水凝胶细胞库的制备 |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| ES2067018T3 (es) | 1988-12-28 | 1995-03-16 | Stefan Miltenyi | Procedimiento y materiales para la separacion en alto gradiente magnetico de materiales biologicos. |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5773224A (en) | 1996-02-12 | 1998-06-30 | Grandics; Peter | Immunoselection system for cell elution |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ATE186235T1 (de) | 1996-04-24 | 1999-11-15 | Claude Fell | Zelltrennungsvorrichtung für biologische flüssigkeiten wie blut |
| US6489458B2 (en) | 1997-03-11 | 2002-12-03 | Regents Of The University Of Minnesota | DNA-based transposon system for the introduction of nucleic acid into DNA of a cell |
| WO1999018129A1 (en) | 1997-10-02 | 1999-04-15 | Sunol Molecular Corporation | Soluble single-chain t-cell receptor proteins |
| EP1034258A2 (en) | 1997-11-13 | 2000-09-13 | The Regents Of The University Of Minnesota | Nucleic acid transfer vector for the introduction of nucleic acid into the dna of a cell |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| JP2002524081A (ja) | 1998-09-04 | 2002-08-06 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 前立腺−特異的膜抗原に特異的な融合受容体およびその使用 |
| WO2000023573A2 (en) | 1998-10-20 | 2000-04-27 | City Of Hope | Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies |
| HK1041454B (en) | 1998-12-24 | 2004-12-31 | 生物安全股份有限公司 | Blood separation system particularly for concentrating hematopoietic stem cells |
| WO2000043551A1 (en) | 1999-01-26 | 2000-07-27 | Cornell Research Foundation, Inc. | Determining viral load in double negative t cells |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| AU2001297703B2 (en) | 2000-11-07 | 2006-10-19 | City Of Hope | CD19-specific redirected immune cells |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| AU2002321581C1 (en) | 2001-08-31 | 2008-09-18 | Adaptimmune Limited | Soluble T cell receptor |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| CA2500392C (en) | 2002-09-27 | 2012-11-27 | The General Hospital Corporation | Microfluidic device for cell separation and uses thereof |
| AU2003271904B2 (en) | 2002-10-09 | 2009-03-05 | Adaptimmune Limited | Single chain recombinant T cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| CA2565581C (en) | 2003-05-02 | 2014-07-08 | Insception Bioscience, Inc. | Apparatus and methods for amplification of blood stem cell numbers |
| US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
| EP1631788B1 (en) | 2003-05-16 | 2007-03-14 | Universite Libre De Bruxelles | Digital holographic microscope for 3d imaging and process using it |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| US8361794B2 (en) | 2004-06-29 | 2013-01-29 | Immunocore Limited | Cells expressing a modified T cell receptor |
| MX2007011218A (es) | 2005-03-23 | 2007-10-17 | Biosafe Sa | Sistema integrado para colectar, procesar y transplantar subconjuntos de celulas, incluyendo celulas madre adultas para medicina regenerativa. |
| EP2567976B1 (en) | 2005-03-23 | 2017-07-19 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| US20090208471A1 (en) | 2006-04-07 | 2009-08-20 | Yun Theodore J | Isolation and Use of Human Regulatory T Cells |
| US20080085532A1 (en) | 2006-09-18 | 2008-04-10 | Jorn Gorlach | Method for determining the immune status of a subject |
| WO2008035631A1 (fr) | 2006-09-20 | 2008-03-27 | Kyowa Hakko Kogyo Co., Ltd. | Procédé de production d'une substance |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| CA2682527C (en) | 2007-03-30 | 2017-07-11 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| WO2009072003A2 (en) | 2007-12-07 | 2009-06-11 | Miltenyi Biotec Gmbh | Sample processing system and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| RS56844B1 (sr) | 2007-12-11 | 2018-04-30 | Univ North Carolina Chapel Hill | Retrovirusni vektori sa modifikovanim polipurinskim nizom |
| CA2710453C (en) | 2007-12-26 | 2019-07-02 | Biotest Ag | Agents targeting cd138 and uses thereof |
| JP5484677B2 (ja) | 2008-01-18 | 2014-05-07 | 三菱重工業株式会社 | 脱水装置 |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| EP4032552B1 (en) | 2008-08-26 | 2023-10-04 | City of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| BRPI0921433A2 (pt) | 2008-10-31 | 2017-06-06 | Abbott Biotherapeutics Corp | uso de anticorpos anti-cs1 para o tratamento de linfomas raros |
| WO2010120561A1 (en) | 2009-04-01 | 2010-10-21 | Genentech, Inc. | Anti-fcrh5 antibodies and immunoconjugates and methods of use |
| US20110070581A1 (en) | 2009-04-27 | 2011-03-24 | Amit Gupta | Separation of Leukocytes |
| CA2777053A1 (en) | 2009-10-06 | 2011-04-14 | The Board Of Trustees Of The University Of Illinois | Human single-chain t cell receptors |
| DK2496698T3 (en) | 2009-11-03 | 2019-04-15 | Hope City | TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRUNCATED T-CELL SELECTION |
| EP2524034A1 (en) | 2010-01-14 | 2012-11-21 | Organogenesis, Inc. | Bioengineered tissue constructs and methods for producing and using thereof |
| US9511151B2 (en) | 2010-11-12 | 2016-12-06 | Uti Limited Partnership | Compositions and methods for the prevention and treatment of cancer |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP5937015B2 (ja) | 2010-12-16 | 2016-06-22 | 株式会社明治 | 遅延型過敏症軽減剤 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| CN110200997A (zh) | 2011-03-23 | 2019-09-06 | 弗雷德哈钦森癌症研究中心 | 用于细胞免疫治疗的方法和组合物 |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN103503438A (zh) | 2011-05-24 | 2014-01-08 | 索尼公司 | 固态图像拾取装置和相机系统 |
| DK2726600T3 (en) | 2011-07-01 | 2017-05-15 | Amgen Inc | Mammalian Cell Culture |
| TR201811128T4 (tr) | 2011-07-18 | 2018-08-27 | Iba Gmbh | Bir hedef hücrenin tersinir şekilde boyama yöntemi. |
| CA2842377C (en) | 2011-07-19 | 2019-08-27 | Ovizio Imaging Systems N.V. | A method and system for detecting and/or classifying cancerous cells in a cell sample |
| WO2013038272A2 (en) | 2011-09-13 | 2013-03-21 | Uti Limited Partnership | Streptavidin mutein exhibiting reversible binding for biotin and streptavidin binding peptide tagged proteins |
| WO2013062365A2 (ko) | 2011-10-26 | 2013-05-02 | 국립암센터 | 변이 ｃｔｌａ4 유전자 이입 ｔ 세포 및 이를 포함하는 항암 면역치료용 조성물 |
| KR102134932B1 (ko) | 2011-11-11 | 2020-07-17 | 프레드 헛친슨 켄서 리서치 센터 | 암을 위한 사이클린 ａ１―표적화된 ｔ―세포 면역요법 |
| US8497124B2 (en) | 2011-12-05 | 2013-07-30 | Factor Bioscience Inc. | Methods and products for reprogramming cells to a less differentiated state |
| JP6850528B2 (ja) | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| RU2746407C1 (ru) | 2012-02-23 | 2021-04-13 | Стейдж Селл Терапеутикс Гмбх | Хроматографическое выделение клеток и других сложных биологических материалов |
| SG10201609210SA (en) | 2012-05-03 | 2016-12-29 | Hutchinson Fred Cancer Res | Enhanced affinity t cell receptors and methods for making the same |
| LT4461308T (lt) | 2012-07-13 | 2025-06-10 | The Trustees Of The University Of Pennsylvania | Car priešnavikinio aktyvumo toksiškumo valdymas |
| AU2013289979A1 (en) | 2012-07-13 | 2015-01-22 | The Trustees Of The University Of Pennsylvania | Methods of assessing the suitability of transduced T cells for administration |
| CA2881981A1 (en) | 2012-08-20 | 2014-02-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| EP2898310B1 (en) | 2012-09-20 | 2019-05-01 | Ovizio Imaging Systems NV/SA | Digital holographic microscope with fluid systems |
| AU2013327136A1 (en) | 2012-10-02 | 2015-04-16 | Memorial Sloan-Kettering Cancer Center | Compositions and methods for immunotherapy |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| CN103305464B (zh) | 2013-06-05 | 2015-04-15 | 南昌大学 | 直接分离cd4+和cd8+淋巴细胞的方法 |
| TWI725931B (zh) | 2013-06-24 | 2021-05-01 | 美商建南德克公司 | 抗ｆｃｒｈ５抗體 |
| CN113354744A (zh) | 2013-12-20 | 2021-09-07 | 弗雷德哈钦森癌症研究中心 | 带标签的嵌合效应分子及其受体 |
| AU2015244039B2 (en) | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| CA2945320A1 (en) | 2014-04-10 | 2015-10-15 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Drug regulated transgene expression |
| BR112016024072B1 (pt) | 2014-04-16 | 2021-02-09 | Juno Therapeutics Gmbh | método in vitro de estimular uma população de células |
| RU2763795C2 (ru) | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| NZ725201A (en) | 2014-04-25 | 2018-05-25 | Bluebird Bio Inc | Improved methods for manufacturing adoptive cell therapies |
| WO2015181253A1 (en) | 2014-05-27 | 2015-12-03 | Fundación Pública Andaluza Progreso Y Salud | Neural progenitor cell population |
| TWI750110B (zh) | 2014-07-21 | 2021-12-21 | 瑞士商諾華公司 | 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症 |
| ES2781175T3 (es) | 2014-07-31 | 2020-08-31 | Novartis Ag | Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico |
| ES2791248T3 (es) | 2014-08-19 | 2020-11-03 | Novartis Ag | Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| BR112017008042A2 (pt) | 2014-10-20 | 2017-12-26 | Juno Therapeutics Inc | métodos e composições para dosagem em terapia de célula adotiva |
| CN107109438B (zh) | 2014-11-05 | 2021-09-03 | 朱诺治疗学股份有限公司 | 用于转导及细胞处理的方法 |
| CA2969456A1 (en) | 2014-12-03 | 2016-06-09 | Juno Therapeutics, Inc. | Methods and compositions for adoptive cell therapy |
| SI3227339T1 (sl) | 2014-12-05 | 2022-02-28 | Memorial Sloan-Kettering Cancer Center | Himerni antigenski receptorji, ki ciljajo na receptor, povezan z G-proteinom, in njihova uporaba |
| EP3227324A4 (en) | 2014-12-05 | 2018-08-29 | Memorial Sloan Kettering Cancer Center | Antibodies targeting g-protein coupled receptor and methods of use |
| KR20240135036A (ko) | 2014-12-05 | 2024-09-10 | 메모리얼 슬로안 케터링 캔서 센터 | B-세포 성숙화 항원을 표적화하는 항체 및 사용 방법 |
| AU2015357526B2 (en) | 2014-12-05 | 2022-03-17 | Eureka Therapeutics, Inc. | Chimeric antigen receptors targeting B-cell maturation antigen and uses thereof |
| BR112017011893A2 (pt) * | 2014-12-05 | 2018-07-24 | City Of Hope | células t modificadas no receptor de antígeno quimérico direcionado para cs1 |
| CN104450614B (zh) | 2014-12-05 | 2017-07-07 | 上海安集协康生物技术股份有限公司 | 一种无动物蛋白源的免疫细胞无血清培养基及其使用方法 |
| US20180140602A1 (en) | 2015-04-07 | 2018-05-24 | Novartis Ag | Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives |
| MX2017012939A (es) | 2015-04-08 | 2018-05-22 | Novartis Ag | Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19. |
| EP3286225B1 (en) | 2015-04-23 | 2020-07-01 | Baylor College of Medicine | Cd5 chimeric antigen receptor for adoptive t cell therapy |
| IL295224B2 (en) | 2015-05-28 | 2025-07-01 | Kite Pharma Inc | Methods of conditioning patients for t cell therapy |
| MX388325B (es) | 2015-05-28 | 2025-03-19 | Kite Pharma Inc | Metodos de diagnostico para tratamiento con linfocitos t. |
| EP3324984A4 (en) | 2015-07-21 | 2019-03-27 | City of Hope | T-LYMPHOCYTES FOR THE EXPRESSION OF CHIMERIC ANTIGEN RECEPTORS |
| AU2016297014B2 (en) | 2015-07-21 | 2021-06-17 | Novartis Ag | Methods for improving the efficacy and expansion of immune cells |
| RU2766690C2 (ru) | 2015-07-28 | 2022-03-15 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Модифицированные моноциты/макрофаги, экспрессирующие химерные антигенные рецепторы, и их применения |
| GB2592821B (en) | 2015-07-31 | 2022-01-12 | Univ Minnesota | Modified cells and methods of therapy |
| WO2017027291A1 (en) | 2015-08-07 | 2017-02-16 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Bispecific car t-cells for solid tumor targeting |
| WO2017035362A1 (en) | 2015-08-26 | 2017-03-02 | Achillion Pharmaceuticals, Inc. | Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses |
| US20180258149A1 (en) | 2015-09-17 | 2018-09-13 | Novartis Ag | Car t cell therapies with enhanced efficacy |
| CA2999037A1 (en) | 2015-09-23 | 2017-03-30 | Cytoimmune Therapeutics, LLC | Flt3 directed car cells for immunotherapy |
| EP3355937A4 (en) | 2015-09-28 | 2019-04-17 | Regents of the University of Minnesota | CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS AS THERAPEUTIC INTERVENTIONS AT AUTO AND ALLO IMMUNITY |
| SG11201803330WA (en) | 2015-10-22 | 2018-05-30 | Juno Therapeutics Gmbh | Methods for culturing cells and kits and apparatus for same |
| CN108884140B (zh) | 2015-12-03 | 2022-10-25 | 朱诺治疗学股份有限公司 | 修饰的嵌合受体及相关组合物和方法 |
| WO2017156479A1 (en) * | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| EP3430072B1 (en) | 2016-03-17 | 2020-07-01 | Merck Patent GmbH | Method for purifying poloxamers |
| KR102499191B1 (ko) | 2016-03-18 | 2023-02-13 | 프레드 허친슨 캔서 센터 | Cd20 면역요법을 위한 조성물 및 방법 |
| CN109415687A (zh) | 2016-04-07 | 2019-03-01 | 蓝鸟生物公司 | 嵌合抗原受体t细胞组合物 |
| MA45341A (fr) | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| CN106754670B (zh) | 2016-11-30 | 2020-02-14 | 湖南省生宝生物科技有限公司 | 一种间充质干细胞无血清培养基及其配制方法和应用 |
| AU2017370644A1 (en) | 2016-12-05 | 2019-06-13 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
| CN106635955B (zh) | 2016-12-16 | 2020-05-19 | 江苏艾尔康生物医药科技有限公司 | 类角膜内皮细胞的获取方法 |
| CN106834218B (zh) | 2017-01-06 | 2021-03-02 | 沈阳艾米奥生物工程技术研发中心有限公司 | 人羊膜上皮干细胞无血清培养基及其培养方法 |
| CN106801032B (zh) | 2017-02-17 | 2021-03-02 | 沈阳艾米奥生物工程技术研发中心有限公司 | 人羊膜上皮干细胞库的构建方法 |
| US12163952B2 (en) | 2017-02-27 | 2024-12-10 | Juno Therapeutics, Inc. | Determining toxicity risk in CAR T-cell therapy |
| DK3372670T3 (da) | 2017-03-09 | 2019-05-20 | Evonik Technochemie Gmbh | Dyrkningsmedier, der omfatter n-acyl-x-glutamindipeptider |
| CN110709700A (zh) * | 2017-04-14 | 2020-01-17 | 朱诺治疗学股份有限公司 | 评估细胞表面糖基化的方法 |
| AU2018275894B2 (en) | 2017-06-02 | 2025-04-24 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| AU2018313950A1 (en) | 2017-08-09 | 2020-02-13 | Juno Therapeutics, Inc. | Methods for producing genetically engineered cell compositions and related compositions |
| CN111263641B (zh) | 2017-08-09 | 2025-10-31 | 朱诺治疗学股份有限公司 | 用于制备基因工程化细胞的方法和组合物 |
| US20210198372A1 (en) | 2017-12-01 | 2021-07-01 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| WO2019113557A1 (en) * | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Process for producing a composition of engineered t cells |
| JP7433230B2 (ja) | 2017-12-08 | 2024-02-19 | ジュノー セラピューティクス インコーポレイテッド | 細胞を培養するための無血清培地配合物およびその使用の方法 |
| CA3094468A1 (en) | 2018-04-05 | 2019-10-10 | Juno Therapeutics, Inc. | Methods of producing cells expressing a recombinant receptor and related compositions |
| US20210121466A1 (en) | 2018-05-03 | 2021-04-29 | Juno Therapeutics, Inc. | Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor |
| CN113474450A (zh) | 2018-08-09 | 2021-10-01 | 朱诺治疗学股份有限公司 | 产生工程化细胞的方法以及所述工程化细胞的组合物 |
| KR20210104713A (ko) | 2018-11-16 | 2021-08-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법 |
| PL3886875T3 (pl) | 2018-11-30 | 2024-09-09 | Juno Therapeutics, Inc. | Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej |
| PL3886894T3 (pl) | 2018-11-30 | 2024-07-01 | Juno Therapeutics, Inc. | Metody dawkowania i leczenia nowotworów b-komórkowych w adoptywnej terapii komórkowej |
| JP2023513434A (ja) | 2020-01-24 | 2023-03-31 | ジュノー セラピューティクス インコーポレイテッド | 養子細胞療法における投与ならびに濾胞性リンパ腫および辺縁帯リンパ腫の処置のための方法 |
| US20230090117A1 (en) | 2020-01-28 | 2023-03-23 | Juno Therapeutics, Inc. | Methods for t cell transduction |
-
2018
- 2018-10-31 EP EP18804808.6A patent/EP3704230B1/en active Active
- 2018-10-31 DK DK18804808.6T patent/DK3704230T3/da active
- 2018-10-31 CN CN201880084155.4A patent/CN111542596B/zh active Active
- 2018-10-31 SG SG11202003688PA patent/SG11202003688PA/en unknown
- 2018-10-31 WO PCT/US2018/058590 patent/WO2019089855A1/en not_active Ceased
- 2018-10-31 KR KR1020207015597A patent/KR20200099132A/ko not_active Ceased
- 2018-10-31 IL IL274293A patent/IL274293B2/en unknown
- 2018-10-31 ES ES18804808T patent/ES2999361T3/es active Active
- 2018-10-31 PL PL18804808.6T patent/PL3704230T3/pl unknown
- 2018-10-31 JP JP2020543731A patent/JP7357626B2/ja active Active
- 2018-10-31 FI FIEP18804808.6T patent/FI3704230T3/fi active
- 2018-10-31 MX MX2020004240A patent/MX2020004240A/es unknown
- 2018-10-31 US US16/760,240 patent/US12258580B2/en active Active
- 2018-10-31 EP EP24207871.5A patent/EP4512823A3/en active Pending
- 2018-10-31 PT PT188048086T patent/PT3704230T/pt unknown
- 2018-10-31 AU AU2018360599A patent/AU2018360599A1/en not_active Abandoned
- 2018-10-31 MA MA050855A patent/MA50855A/fr unknown
- 2018-10-31 CA CA3084514A patent/CA3084514A1/en active Pending
- 2018-10-31 BR BR112020008340-2A patent/BR112020008340A2/pt unknown
-
2023
- 2023-09-26 JP JP2023163684A patent/JP7850117B2/ja active Active
-
2025
- 2025-02-11 US US19/051,032 patent/US20250171739A1/en active Pending
- 2025-07-07 AU AU2025205183A patent/AU2025205183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA50855A (fr) | 2020-09-09 |
| FI3704230T3 (fi) | 2024-12-27 |
| EP3704230A1 (en) | 2020-09-09 |
| KR20200099132A (ko) | 2020-08-21 |
| IL274293B2 (en) | 2025-11-01 |
| JP2023182652A (ja) | 2023-12-26 |
| IL274293B1 (en) | 2025-07-01 |
| EP4512823A3 (en) | 2025-05-14 |
| JP7850117B2 (ja) | 2026-04-22 |
| CN111542596A (zh) | 2020-08-14 |
| JP7357626B2 (ja) | 2023-10-06 |
| ES2999361T3 (en) | 2025-02-25 |
| WO2019089855A1 (en) | 2019-05-09 |
| JP2021501604A (ja) | 2021-01-21 |
| BR112020008340A2 (pt) | 2020-11-17 |
| AU2018360599A1 (en) | 2020-05-07 |
| PL3704230T3 (pl) | 2025-02-24 |
| CA3084514A1 (en) | 2019-05-09 |
| DK3704230T3 (da) | 2025-01-02 |
| US20250171739A1 (en) | 2025-05-29 |
| IL274293A (en) | 2020-06-30 |
| EP4512823A2 (en) | 2025-02-26 |
| CN111542596B (zh) | 2025-01-14 |
| AU2025205183A1 (en) | 2025-08-07 |
| US20200354677A1 (en) | 2020-11-12 |
| US12258580B2 (en) | 2025-03-25 |
| SG11202003688PA (en) | 2020-05-28 |
| EP3704230B1 (en) | 2024-10-23 |
| PT3704230T (pt) | 2024-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004240A (es) | Proceso para generar composiciones terapeuticas de celulas modificadas. | |
| MX2020005908A (es) | Proceso para producir una composicion de celulas t modificadas. | |
| MX2020004239A (es) | Proceso para producir una composicion de celulas t. | |
| MX2022005389A (es) | Terapia de celulas t con receptor de antigeno quimerico. | |
| MX2019011570A (es) | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. | |
| MX2019006438A (es) | Produccion de celulas modificadas para terapia de celulas adoptivas. | |
| MX2016013747A (es) | Métodos para aislar, cultivar y diseñar genéticamente poblaciones de células inmunes para terapia adoptiva. | |
| BR112022002955A2 (pt) | Células imunes para terapias de células adotivas | |
| MX2020006689A (es) | Composiciones de vcar y metodos de uso. | |
| MX2021008143A (es) | Metodos para cosechar cultivos de celulas de mamifero. | |
| MX2018005274A (es) | Metodos para la generacion de celulas-t a partir de celulas madre y metodos inmunoterapeuticos que utilizan las celulas-t. | |
| MX2018004146A (es) | Células modificadas genéticamente que comprenden un gen mano modificado de la región constante alfa del receptor de células t. | |
| EA201992615A1 (ru) | Способы выделения клеток без использования трансгенных маркерных последовательностей | |
| BR112016028512A8 (pt) | método de cultivo de uma célula de mamífero e método de produção de uma proteína recombinante | |
| MX2021005021A (es) | Proceso para producir celulas t geneticamente modificadas. | |
| WO2015154012A8 (en) | Clonogenic natural killer (nk) cell populations and methods of producing and using such populations | |
| EP4461743A3 (en) | T cell modification | |
| EP4289944A3 (en) | Method for preparing genetically-modified t cells which express chimeric antigen receptor | |
| MX2016010171A (es) | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. | |
| SG10201809452RA (en) | Cell culture compositions with antioxidants and methods for polypeptide production | |
| MX2021002702A (es) | Metodos para expandir celulas t del receptor de antigeno quimerico especificas de antigenos, composiciones y usos relacionados con las mismas. | |
| ZA202204993B (en) | Expression of nitrogenase polypeptides in plant cells | |
| SA522432641B1 (ar) | T تركيبة لزراعة الخلية التنظيمية واستخدامها | |
| ZA202107143B (en) | Expression of nitrogenase polypeptides in plant cells | |
| CL2010000774A1 (es) | Medio para el cultivo de celulas de mamiferos que comprende ademas de los nutrientes habituales de los medios de cultivo basales para cultivo de celulas de mamiferos, sobrenadante de la fraccion ii+iii del plasma humano segun el metodo de cohn; procedimiento de preparacion; y su uso. |